Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
AEGR's Cash to Debt is ranked lower than
94% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. AEGR: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
AEGR' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 8.29 Max: No Debt
Current: 0.16
Equity to Asset 0.13
AEGR's Equity to Asset is ranked lower than
91% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. AEGR: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
AEGR' s Equity to Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.40 Max: 0.87
Current: 0.13
0.13
0.87
F-Score: 3
Z-Score: -1.78
M-Score: -4.38
WACC vs ROIC
11.68%
-30.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -43.86
AEGR's Operating margin (%) is ranked higher than
55% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. AEGR: -43.86 )
Ranked among companies with meaningful Operating margin (%) only.
AEGR' s Operating margin (%) Range Over the Past 10 Years
Min: -128.43  Med: -72.65 Max: -16.86
Current: -43.86
-128.43
-16.86
Net-margin (%) -56.92
AEGR's Net-margin (%) is ranked higher than
53% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. AEGR: -56.92 )
Ranked among companies with meaningful Net-margin (%) only.
AEGR' s Net-margin (%) Range Over the Past 10 Years
Min: -130.51  Med: -77.69 Max: -24.87
Current: -56.92
-130.51
-24.87
ROE (%) -99.76
AEGR's ROE (%) is ranked lower than
82% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. AEGR: -99.76 )
Ranked among companies with meaningful ROE (%) only.
AEGR' s ROE (%) Range Over the Past 10 Years
Min: -105.89  Med: -76.69 Max: -28.82
Current: -99.76
-105.89
-28.82
ROA (%) -28.27
AEGR's ROA (%) is ranked lower than
51% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. AEGR: -28.27 )
Ranked among companies with meaningful ROA (%) only.
AEGR' s ROA (%) Range Over the Past 10 Years
Min: -189.06  Med: -58.90 Max: -6.36
Current: -28.27
-189.06
-6.36
ROC (Joel Greenblatt) (%) -202.16
AEGR's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. AEGR: -202.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEGR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -88019.35  Med: -34882.76 Max: -897.06
Current: -202.16
-88019.35
-897.06
EBITDA Growth (3Y)(%) -21.90
AEGR's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. AEGR: -21.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEGR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.95 Max: 44.8
Current: -21.9
0
44.8
EPS Growth (3Y)(%) -12.70
AEGR's EPS Growth (3Y)(%) is ranked lower than
59% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. AEGR: -12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEGR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -6.35 Max: 26.3
Current: -12.7
0
26.3
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AEGR Guru Trades in Q2 2015

Jim Simons 159,575 sh (New)
» More
Q3 2015

AEGR Guru Trades in Q3 2015

Jim Simons 232,800 sh (+45.89%)
» More
Q4 2015

AEGR Guru Trades in Q4 2015

John Paulson 26,400 sh (New)
Paul Tudor Jones 22,900 sh (New)
Jim Simons 125,900 sh (-45.92%)
» More
Q1 2016

AEGR Guru Trades in Q1 2016

Jim Simons 776,429 sh (+516.70%)
Paul Tudor Jones 62,300 sh (+172.05%)
John Paulson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:217950, TSE:4584, TSX:AUP, AMEX:ATNM, AMEX:PLX, ASX:ACR » details
Traded in other countries:KYE.Germany,
Aegerion Pharmaceuticals Inc is a biopharmaceutical company. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide.

Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.

Ratios

vs
industry
vs
history
P/B 0.87
AEGR's P/B is ranked higher than
92% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. AEGR: 0.87 )
Ranked among companies with meaningful P/B only.
AEGR' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 5.40 Max: 24.7
Current: 0.87
0.87
24.7
P/S 0.23
AEGR's P/S is ranked higher than
99% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. AEGR: 0.23 )
Ranked among companies with meaningful P/S only.
AEGR' s P/S Range Over the Past 10 Years
Min: 0.22  Med: 6.82 Max: 1693.72
Current: 0.23
0.22
1693.72
POCF 146.35
AEGR's POCF is ranked lower than
94% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. AEGR: 146.35 )
Ranked among companies with meaningful POCF only.
AEGR' s POCF Range Over the Past 10 Years
Min: 8.76  Med: 19.14 Max: 526.36
Current: 146.35
8.76
526.36
Current Ratio 1.33
AEGR's Current Ratio is ranked lower than
85% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. AEGR: 1.33 )
Ranked among companies with meaningful Current Ratio only.
AEGR' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 6.77 Max: 17.43
Current: 1.33
0.03
17.43
Quick Ratio 0.83
AEGR's Quick Ratio is ranked lower than
88% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. AEGR: 0.83 )
Ranked among companies with meaningful Quick Ratio only.
AEGR' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 6.73 Max: 17.43
Current: 0.83
0.03
17.43
Days Inventory 361.22
AEGR's Days Inventory is ranked lower than
89% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. AEGR: 361.22 )
Ranked among companies with meaningful Days Inventory only.
AEGR' s Days Inventory Range Over the Past 10 Years
Min: 59.63  Med: 100.62 Max: 141.61
Current: 361.22
59.63
141.61
Days Sales Outstanding 18.27
AEGR's Days Sales Outstanding is ranked higher than
83% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. AEGR: 18.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEGR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.47  Med: 48.20 Max: 56.93
Current: 18.27
39.47
56.93
Days Payable 61.64
AEGR's Days Payable is ranked higher than
52% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. AEGR: 61.64 )
Ranked among companies with meaningful Days Payable only.
AEGR' s Days Payable Range Over the Past 10 Years
Min: 246.71  Med: 273.86 Max: 301
Current: 61.64
246.71
301

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.03
AEGR's Price/Median PS Value is ranked higher than
99% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. AEGR: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
AEGR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 1.09 Max: 139.1
Current: 0.03
0.07
139.1
Earnings Yield (Greenblatt) (%) -35.77
AEGR's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. AEGR: -35.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEGR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -40.98  Med: 0.00 Max: 0
Current: -35.77
-40.98
0

More Statistics

Revenue (TTM) (Mil) $216.2
EPS (TTM) $ -4.21
Beta2.13
Short Percentage of Float33.71%
52-Week Range $1.60 - 21.21
Shares Outstanding (Mil)29.50
» More Articles for NAS:AEGR

Headlines

Articles On GuruFocus.com
Stocks Reach 5-Year Lows Apr 11 2016 
Stocks Reach 5-year Lows Apr 04 2016 
Stocks Fall to 5-Year Lows Mar 28 2016 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 

More From Other Websites
AEGERION PHARMACEUTICALS, INC. Financials May 24 2016
Robbins Arroyo LLP Is Investigating the Officers and Directors of Aegerion Pharmaceuticals, Inc.... May 19 2016
ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : May 19, 2016 May 19 2016
Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
IBB’s Holdings Surge on Positive Market Sentiment May 17 2016
​Aegerion on the hunt for rare drug makers in need of sales help May 17 2016
Aegerion (AEGR) Misses Q1 Earnings Estimates, Cuts View May 17 2016
Edited Transcript of AEGR earnings conference call or presentation 16-May-16 9:00pm GMT May 16 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 16 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 16 2016
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results May 16 2016
Aegerion reports 1Q loss May 16 2016
Aegerion reports 1Q loss May 16 2016
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results May 16 2016
Q1 2016 Aegerion Pharmaceuticals Inc Earnings Release - After Market Close May 16 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into... May 13 2016
Faruqi & Faruqi, LLP is Investigating Aegerion Pharmaceuticals, Inc. (AEGR) on Behalf of its... May 13 2016
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Hold Aegerion Pharmaceuticals,... May 13 2016
Aegerion Enters into Settlement Agreement with DoJ and SEC May 13 2016
Aegerion shares battered on news it will plead guilty to misdemeanors, pay $40M May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)